生血宝合剂治疗苹果酸舒尼替尼骨髓抑制的疗效观察

Effect of Shengxuebao mixture on bone marrow suppression induced by sunitinib maleate in renal cell carcinoma patients

目的观察生血宝合剂在治疗因服用苹果酸舒尼替尼出现骨髓抑制的临床有效性和安全性。方法对26例因服用苹果酸舒尼替尼(索坦)出现骨髓抑制的肾细胞癌患者,按中性粒细胞和血小板程度(Ⅰ级或Ⅱ级不良反应)分为两组,中性粒细胞或血小板任一指标为Ⅱ级不良反应均入中度组,给予生血宝合剂15 ml口服,每日3次,连续服用2周,服用生血宝期间索坦不减量。记录各组患者治疗前后血小板、中性粒细胞、血红蛋白的变化。观察治疗过程中不良反应的发生率。结果两组患者在服药1周后血小板、中性粒细胞、血红蛋白均明显上升(P<0.01),在服药2周后与服药前比较有明显差异(P<0.01),与服药1周比较亦有明显上升(P<0.01)。中度组各指标的上升率要大于轻度组(P<0.01)。未见明显不良反应发生。结论生血宝合剂在治疗苹果酸舒尼替尼致骨髓抑制方面有较好疗效,有效时间较长,对较严重的骨髓抑制患者的效果更明显,安全性较好。

Objective To observe the efficacy and safety of Shengxuebao（SXB） mixture in the treatment of bone marrow suppression（BMS）caused by sunitinib maleate（Sutent）.Methods Twenty-six renal cell carcinoma patients with BMS induced by sunitinib were enrolled and divided into two groups： mild group and moderate group by degrees of neutrophils（N） and platelet（PLT）（adverse events Ⅰ or Ⅱ）.Both groups were given 15 ml of SXB three times a day for two weeks.Changes in PLT,N and Hb were recorded.The incidence of adverse events was observed.Results One week after medication,the PLT,N and Hb levels of both groups continued to increase obviously with statistical significance（P＆lt;0.01）.Two weeks after medication,the PLT,N and Hb levels of both groups continued to increase obviously with statistical significance（P＆lt;0.01）.Levels of moderate group increased more significantly than those of mild group.Conclusion SXB has sustainable and good effect on BMS,especially on severe BMS.No obvious side effect is observed.